- Home
- VMO vs AVDL Comparison
VMO vs AVDL Comparison
Compare VMO & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMO
- AVDL
- Stock Information
- Founded
- VMO 1992
- AVDL 2015
- Country
- VMO United States
- AVDL Ireland
- Employees
- VMO N/A
- AVDL 188
- Industry
- VMO Trusts Except Educational Religious and Charitable
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- VMO Finance
- AVDL Health Care
- Exchange
- VMO Nasdaq
- AVDL Nasdaq
- Market Cap
- VMO 662.3M
- AVDL 764.3M
- IPO Year
- VMO N/A
- AVDL 1996
- Fundamental
- Price
- VMO $9.73
- AVDL $7.91
- Analyst Decision
- VMO
- AVDL Strong Buy
- Analyst Count
- VMO 0
- AVDL 7
- Target Price
- VMO N/A
- AVDL $18.86
- AVG Volume (30 Days)
- VMO 254.7K
- AVDL 1.5M
- Earning Date
- VMO 01-01-0001
- AVDL 03-03-2025
- Dividend Yield
- VMO 4.39%
- AVDL N/A
- EPS Growth
- VMO N/A
- AVDL N/A
- EPS
- VMO N/A
- AVDL N/A
- Revenue
- VMO N/A
- AVDL $169,117,000.00
- Revenue This Year
- VMO N/A
- AVDL $51.49
- Revenue Next Year
- VMO N/A
- AVDL $32.18
- P/E Ratio
- VMO N/A
- AVDL N/A
- Revenue Growth
- VMO N/A
- AVDL 504.79
- 52 Week Low
- VMO $7.86
- AVDL $7.39
- 52 Week High
- VMO $9.87
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- VMO 40.89
- AVDL 43.28
- Support Level
- VMO $9.83
- AVDL $7.45
- Resistance Level
- VMO $9.89
- AVDL $7.97
- Average True Range (ATR)
- VMO 0.07
- AVDL 0.37
- MACD
- VMO -0.01
- AVDL -0.01
- Stochastic Oscillator
- VMO 0.00
- AVDL 33.82
About VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.